low cost glp 1 GLP-1 costs rise, but there are ways to save on weight-loss drugs Hims Inc. - Hims &

Description

EMERGING TRENDS AND POTENTIAL PRACTICE IMPLICATIONS Research on GLP-1 agonists suggests that these medications may be effective treatments for conditions beyond diabetes and obesity, suggesting a broad potential impact on health care

You should discontinue GLP-1 therapy during active inflammation and restart only after remission is achieved, under provider guidance

Footnotes An agonist is a drug (or other substance) that binds to a specific receptor in the body and turns it on, triggering the same biological response the natural molecule would

* Additional details on other secondary outcomes other than the change in body weight can be found at as NCT03954834 (SURPASS-1), NCT03987919 (SURPASS-2), NCT03882970 (SURPASS-3), NCT03730662 (SURPASS-4), NCT04039503 (SURPASS-5), NCT04537923 (SURPASS-6), NCT04255433 (SURPASS-CVOT), NCT03861052(SURPASS J-mono), NCT04093752 (SURPASS-AP-Combo), and NCT04184622 (SURMOUNT-1)